Effects of adrenal medulla graft on recovery of GABAergic and dopaminergic neuron deficits in mice: Behavioural, pharmacological and immunohistochemical study

Behavioural Brain Research

Volumn 140, Issue 1-2, 2003, Pages 185-193

  Jousselin Hosaja, M ^a   Tobin, C ^a   Venault, P ^a   Joubert, C ^a   Chapouthier, G ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Adrenal medulla; Graft; Immunohistochemistry; Mice; Open field; Quinolinic acid; Striatum; Tetrabenazine

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CATECHOLAMINE; DOPAMINE; NEURONAL VESICULAR MONOAMINE TRANSPORTER TYPE 2; PROTEIN; QUINOLINIC ACID; TETRABENAZINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL MEDULLA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN GRAFT; CELL INTERACTION; CELL LOSS; CHROMAFFIN CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EMOTION; GROOMING; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; REARING;

ADRENAL MEDULLA; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CORPUS STRIATUM; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MOTOR ACTIVITY; NEURONS; NEUROPEPTIDES; NEUROTOXINS; QUINOLINIC ACID; TETRABENAZINE; TYROSINE 3-MONOOXYGENASE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0037452856     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00315-7     Document Type: Article

References (63)

1. Agmo A., Belzung C., Giordano M. Interactions between dopamine and GABA in the control of ambulatory activity. J. Neural Trans. 103:1996;925-934.
2. Archer J. Tests for emotionality in rats and mice: a review. Anim. Behav. 173:(21):1973;205-235.
3. Asher S.W., Aminoff M.J. Tetrabenazine and movement disorders. Neurology. 31:1981;1051-1054.
4. Barros H.M., Tannhauser S.L., Tannhauser M.A., Tannhauser M. The effects of GABAergic drugs on grooming behavior in the open field. Pharmacol. Toxicol. 74:1994;339-344.
5. Baumeiter A.A., Hawkins M.F., Anderson-Moore L.L., Anticich T.G., Higgins T.D., Griffin P. Effects of bilateral injection of GABA into the Substantia nigra on spontaneous behavior and measures of analgesia. Neuropharmacology. 27:1988;817-821.
6. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Schwartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-174.
7. Berridge K.C., Whishaw I.Q. Cortex, striatum and cerebellum: control of serial order in a grooming sequence. Exp. Brain Res. 90:1992;275-290.
8. Bohnen N.I., Koeppe R.A., . Meyer P., Ficaro E., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 54:2000;1753-1759.
9. Bormann J., Clapham D.E. Gamma-aminobutyric acid receptor channels in adrenal chromaffin cells: a patch clamp study. Proc. Natl. Acad. Sci. USA. 8:1985;2168-2172.
10. Bunney B.S., Achajanian G.K. D-amphetamine-induced inhibition of central dopaminergic neurons: mediation by a striato-nigral feed-back pathway. Science. 192:1976;391-393.
11. Collier T.J., Springer J.E. Co-grafts of embryonic dopamine neurons and adult sciatic nerve into the denervated striatum enhance behavioral and morphological recovery in rats. Exp. Neurol. 114:1991;343-350.
12. Cromwell H.C., Berridge K.C. Implementation of action sequences by a neostriatal site: a lesion mapping study of grooming syntax. J. Neurosci. 16:1996;3444-3458.
13. Date I., Ohomoto T. Neuronal transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsuled dopamine-secreting cell grafting. Exp. Neurol. 137:1996;333-344.
14. Dishman R.K., Dunn A.L., Youngstedt S.D., Davis J.M., Burgess M.L., Wilson S.P., Wilson M.A. Increased open field locomotion and decreased striatal GABAA binding after activity wheel running. Physiol. Behav. 60:1996;699-705.
15. Dray A. The striatum and substantia nigra: a commentary on their relationships. Neuroscience. 41:1979;1407-1439.
16. Eaton M.J., Martinez M., Karmally S., Lopez T., Sagen J. Initial characterization of the transplant of immortalized chromaffin cells for the attenuation of chronic neuropathic pain. Cell Transplant. 9:2000;637-656.
17. Fornaguera J., Carey R.J., Huston J.P., Schwarting R.K.W. Behavioral asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion. Brain Res. 664:1994;178-188.
18. Freed W.J., Morihisa J.M., Spoor E., Hoffer B.J., Olson L., Seiger A., Wyatt R.J. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior. Nature. 292:1981;351-352.
19. Ghorayeb I., Puschban Z., Fernagut P.O., Scherfler C., Rouland R., Wenning G.K., Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp. Neurol. 167:2001;133-147.
20. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-253.
21. Guidotti A., Hanbauer I. Participation of GABA/benzodiazepine receptor system in the adrenal chromaffin cell function. Adv. Biochem. Psychopharmacol. 42:1986;165-172.
22. Harsing L.G., Zigmond M.J. Dopaminergic inhibition of striatal GABA release after -6-hydroxydopamine. Brain Res. 738:1996;142-145.
23. Hasenöhrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K., Huston J.P. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides. 34:2000;272-280.
24. Hsu S.M., Raine L. Protein A, avidin, and biotin in immunohistochemistry. J. Histochem. Cytochem. 29:1981;1349-1353.
25. Jousselin-Hosaja M. A descriptive and quantitative morphometric study of long-term mouse adrenal medulla grafts implanted into the putamen: effect of nerve growth factor injected at grafting. Brain Res. 627:1993;275-286.
26. Jousselin-Hosaja M., Collery M., Delacour J. Effects of adrenal medulla grafts on memory capacities of rats after hippocampal lesions. Neuroscience. 59:1994;275-284.
27. Jousselin-Hosaja M., Venault P., Tobin C., Joubert C., Delacour J., Chapouthier G. Involvement of adrenal medulla grafts in the open field behaviour. Behav. Brain Res. 121:2002;29-37.
28. Kataoka Y., Gutman Y., Guidotti A., Panula P., Wroblewski J., Cosenza-Murphy D., Wu J.Y., Costa E. Intrinsic GABAergic system of adrenal chromaffin cells. Proc. Natl. Acad. Sci. USA. 81:1984;3218-3222.
29. Lane J.D., Smith J.E., Shea P.A., McBride W.J. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci. 19:1976;1663-1667.
30. Lehericy S., Brandel J.P., Hirsch E.C., Anglande P., Villares P., Scherman D., Duyckaerts C., Javoy-Agid F., Agid Y. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 659:1994;1-9.
31. Livett B.G., Dean D.M., Whelan L.G., Udenfriend S., Rossier J. Co-release of enkephalin and catecholamines from cultured adrenal chromaffin cells. Nature. 289:1981;317-319.
32. Luthman J., Bassen M., Fredriksson A., Archer T. Functional changes induced by neonatal cerebral 6-hydroxydopamine treatment: effects of dose levels on behavioral parameters. Behav. Brain Res. 82:1997;213-221.
33. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20:1999;424-429.
34. Nishino H., Ono T., Shibata R., Kawamata S., Watanabe H., Shiosaka S., Tohyama M., Karadi Z. Adrenal medullary cells transmute into dopaminergic neurons in dopamine-depleted rat caudate and ameliorate motor disturbances. Brain Res. 445:1988;325-337.
35. Ohmori Y., Okada Y., Watanabe T. Immunohistochemical localization of serotonin, galanin, cholecystokinin, and methionine-enkephalin in adrenal medullary cells of the chicken. Tissue Cell Res. 29:1997;199-205.
36. Osborne P.G. A GABAergic mechanism in the medial septum influences cortical arousal and locomotor activity but not a previously learned spatial discrimination task. Neurosci. Lett. 173:1994;63-66.
37. Osborne P.G., Mataga N., Onoe H., Watanabe Y. Behavioral activation by stimulation of a GABAergic mechanism in the preoptic area of rat. Neurosci. Lett. 158:1993;201-204.
38. Oset-Gasque M.J., Castro E., Gonzalez M.P. GABAergic mechanisms in bovine adrenal chromaffin cells: their role in the regulation of catecholamine secretion. Erdö S.L. GABA outside the CNS. 1992;167-181 Springer.
39. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:1990;254-258.
40. Perlman S.H., Levivier M., Collier T.J., Sladek J.R. Jr, Gash D.M. Striatal implants protect the host striatum against quinolinic acid toxicity. Exp. Brain Res. 84:1991;303-310.
41. Sanberg P.R., Coyle J.T. Scientific approaches to Huntington's disease. Crit. Rev. Clin. Neurobiol. 1:1984;1-44.
42. Sanberg P.R., Calderon S.F., Giordano M., Tew J.M., Norman A.B. The quinolinic acid model of huntington's disease: locomotor abnormalities. Exp. Neurol. 105:1989;45-53.
43. Sandoval M.R., Palermo-Neto J. Effect of manipulation of the GABA systems on dopamine-related behaviors. Braz. J. Med. Biol. Res. 28:1995;88-99.
44. Sanger D.J. GABA and the behavioral effects of anxiolytic drugs. Life Sci. 36:1985;1503-1513.
45. Scherfler C., Puschban Z., Ghorayeb I., Goebel G.P., Tison F., Jellinger K., Poewe W., wenning G.K. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience. 99:2000;43-54.
46. Slotnick BM, Leonard CM. A stereotaxic atlas of the albino mouse forebrain. US Department of Health, Education and Welfare Public Health Service, Dhew Publication No 1975: AMD.
47. Spielewoy C., Roubert C., Hamon M., Nosten-Bertrand M., Bentancur C., Giros B. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 11:2000;279-290.
48. Spruijt B.M., van Hooff J.A., Gispen W.H. Ethology and neurobiology of grooming behavior. Physiol. Rev. 72:1992;825-852.
49. Stenevi U., Björklund A., Svendgaard N.A. A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Res. 114:1976;1-20.
50. Strömberg I., Herrera-Marschitz M., Ungerstedt U., Ebendal T., Olson L. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp. Brain Res. 60:1985;335-349.
51. Sortwell C.E., Pappas G.D., Sagen J. Chromaffin cell xenografts in the rat neocortex can produce antidepressive activity in the forced swimming test. Exp. Brain Res. 103:1995;59-69.
52. Tatter S.B., Galpern W.R., Hoogeveen A.T., Isacson O. Effects of striatal excitocity on huntingtin-like immunoreactivity. Neuroreport. 6:1995;1125-1129.
53. Unsicker K. The trophic cocktail made by adrenal chromaffin cells. Exp. Neurol. 123:1993;167-173.
54. van Abeelen J.H., van den Heuvel C.M. Behavioural responses to novelty in two inbred mouse strain after intrahippocampal naloxone and morphine. Behav. Brain Res. 2:1982;199-207.
55. Vadasz C., Kobor G., Lajtha A. Motor activity and the mesotelencephalic dopamine function. I. High-resolution temporal and genetic analysis of open-field behavior. Behav. Brain Res. 48:1992;29-39.
56. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294:1995;577-583.
57. Vander Borght T.M., Sima A.A., Kilburn M.R., Desmond T.J., Kahl D.E., Frey K.A. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 68:1995;955-962.
58. Vezzani A., Forloni G.L., Serafini R., Rizzi M., Samanin R. Neurodegenerative effects induced by chromic infusion of quinolinic acid in rat striatum and hippocamus. Eur. J. Neurosci. 3:1990;40-46.
59. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., Caron M.G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron. 19:1997;1285-1296.
60. Walsh R.N., Cummins R.A. The open-field test: a critical review. Psychol. Bull. 83:1976;482-504.
61. Watts C., Dunnett S.B. Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington's disease: implication for timing of surgical intervention. J. Neurosurg. 89:1998;267-274.
62. Wenning G.K., Granata R., Laboyrie P.M., Quinn N.P., Jenner P., Marsden C.D. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov. Disord. 11:1996;522-532.
63. Westerling P., Lindgren S., Hoglund U. Dopamine mediated behavior and GABA influence. Pharmacol. Biochem. Behav. 31:1988;593-596.